Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MANKIND.NS
BuyPremium GrowerMankind Pharma Limited · Healthcare · India · $10.1B · Avg Vol: $9M/d
69
StockRankGet insider-trade alerts
Q
69
V
26
M
68
P/E (TTM)
45.8x
ROE
11.7%
D/E
0.4x
Dividend %
0.0%
COMPANY DESCRIPTION
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 87.5B | 102.6B | 122.1B | 142.8B | 17.7% | 147.9B | 160.5B | 179.2B | 12.0% |
| EPS (INR) | 32.00 | 47.75 | 49.28 | 46.35 | 13.1% | 49.58 | 51.10 | 62.89 | 16.5% |
| Shares | 400.6M | 400.6M | 412.6M | 412.8M | +3.1% | 413.0M | — | — | — |
| Debt | 1.7B | 2.1B | 85.1B | 63.1B | 233.4% | 63.3B | — | — | — |
| Equity | 74.4B | 93.6B | 143.3B | 163.0B | 29.9% | — | — | — | — |
| Op CF | 18.1B | 21.5B | 24.1B | 31.2B | 19.8% | 31.3B | — | — | — |
| Inv CF | -10.5B | -20.8B | -126.8B | -2.0B | — | — | — | — | — |
| Fin CF | -7.4B | 52.7M | 102.3B | -29.5B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-12.6%
SMA 50SMA 200
Close
$23.73
RSI (14)
32.9
52W High
$28.02
From 52W High
0.8%
SCORE BREAKDOWN
Quality
69
ROIC
13.7%80.4
ROE
11.7%75.4
GP/Assets
37.1%74.5
Op. Margin
20.6%83.7
FCF/Assets
8.5%82.7
Piotroski
783.9
Int. Cover
4.7x50.9
D/E Ratio
0.38x35.4
Current Ratio
1.07x12.9
Value
26
P/E (TTM)
45.8x23.9
EV/EBITDA
25.6x25.6
P/FCF
40.1x37.0
P/B
5.7x24.4
P/S
6.3x35.7
Div Yield
0.0%0.6
Momentum
68
52W High %
85%75.0
RS 6M
9%73.4
SMA 50/200
1.08x72.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+43%50.3
Q Growth
30%63.3
FUNDAMENTALS
Market Cap
$10.1B
P/E (Forward)
32.1x
Gross Margin
70.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MANKIND.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MANKIND.NS | Mankind Pharma Limited(you) | $10.1B | 69 | Buy |
| CIPLA.NS | Cipla Limited | $11.8B | 68 | Buy |
| ZYDUSLIFE.NS | Zydus Lifesciences Limited | $12.1B | 68 | Buy |
| LAURUSLABS.NS | Laurus Labs Limited | $11.1B | 75 | Buy |
| ALKEM.NS | Alkem Laboratories Limited | $6.5B | 69 | Buy |
| DRREDDY.NS | Dr. Reddy's Laboratories Limited | $10.1B | 50 | Hold |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| AUROPHARMA.NS | Aurobindo Pharma Limited | $10.3B | 91 | Strong Buy |
| LUPIN.NS | Lupin Limited | $10.2B | 91 | Strong Buy |
| DIVISLAB.NS | Divi's Laboratories Limited | $26.8B | 73 | Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%